General Information of Disease (ID: DISJMBMM)

Disease Name Leukopenia
Synonyms leukocytopenia; leucopenia; White blood cell decreased
Disease Class 4B00: Neutropenia
Definition A laboratory test result indicating a decreased number of white blood cells in the peripheral blood.
Disease Hierarchy
DIS17G9I: Leukocyte disorder
DISJMBMM: Leukopenia
ICD Code
ICD-11
ICD-11: 4B00.0Z
Expand ICD-11
'4B00.0Z
Disease Identifiers
MONDO ID
MONDO_0003785
MESH ID
D007970
UMLS CUI
C0023530
MedGen ID
6073
HPO ID
HP:0001882
SNOMED CT ID
84828003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
APL-001 DMLEFIN Investigative NA [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 54 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CD79B TTBN5I7 Limited Genetic Variation [2]
CTLA4 TTI2S1D Limited Altered Expression [3]
CXCR4 TTBID49 Limited Biomarker [4]
FLT3 TTGJCWZ Limited Genetic Variation [5]
IFNA2 TTSIUJ9 Limited Biomarker [6]
IL2 TTF89GD Limited Biomarker [7]
PML TTLH9NY Limited Biomarker [8]
RRM1 TTWP0NS Limited Genetic Variation [9]
AOC1 TTM3B5R Disputed Genetic Variation [10]
ABCC2 TTFLHJV moderate Genetic Variation [11]
ACKR1 TTKY2NS moderate Genetic Variation [12]
CD40LG TTIJP3Q moderate Biomarker [13]
CSF3R TTC70AJ moderate Biomarker [14]
CYP2C19 TTZ58XG moderate Genetic Variation [15]
CYP2C9 TTR40YJ moderate Genetic Variation [15]
CYP3A5 TTHS0OK moderate Biomarker [16]
DHFR TTYZVDJ moderate Genetic Variation [17]
G6PC TTBQMJ8 moderate Genetic Variation [18]
GEM TTAZF9M moderate Genetic Variation [19]
IL11 TTGUYTR moderate Biomarker [20]
KAT6A TT6O1J0 moderate Genetic Variation [21]
MERTK TTO7LKR moderate Biomarker [22]
NCAM1 TTVXPHT moderate Genetic Variation [23]
SLC29A1 TTLXAKE moderate Genetic Variation [24]
TDP1 TT64IHJ moderate Genetic Variation [25]
TYMS TTP1UKZ moderate Genetic Variation [17]
ABCC4 TTUEAFL Strong Genetic Variation [26]
ADK TTL732K Strong Genetic Variation [27]
ATP4A TTF1QVM Strong Altered Expression [28]
BRCA2 TTUARD6 Strong Genetic Variation [29]
CES1 TTMF541 Strong Genetic Variation [30]
CFI TT6ATLX Strong Genetic Variation [31]
CPB1 TT4UJX5 Strong Genetic Variation [32]
CYP2B6 TTMH124 Strong Biomarker [33]
FDXR TT3W4IX Strong Genetic Variation [34]
FTO TTFW3BT Strong Genetic Variation [35]
GADD45B TTMDW9L Strong Genetic Variation [36]
GGH TTZJRL0 Strong Genetic Variation [37]
GRK3 TT5A4DX Strong Biomarker [38]
GSTA1 TT4P8DE Strong Genetic Variation [39]
HAX1 TT21BYA Strong Genetic Variation [40]
IMPDH1 TT3GRLK Strong Genetic Variation [41]
IMPDH2 TTTB4UP Strong Genetic Variation [42]
MTHFR TTQWOU1 Strong Genetic Variation [43]
NAAA TTMN4HY Strong Biomarker [44]
PDE4B TTVIAT9 Strong Genetic Variation [45]
PKN1 TTSL41O Strong Biomarker [46]
PRKAR1A TTNAHEX Strong Genetic Variation [47]
SLC17A5 TTFSUIA Strong Biomarker [48]
SLC19A1 TT09I7D Strong Genetic Variation [49]
SLCO1B1 TTFGXEB Strong Biomarker [50]
TFF1 TTNOJIZ Strong Biomarker [51]
UMPS TTAFJUD Strong Genetic Variation [52]
WAS TTE8T73 Strong Biomarker [53]
------------------------------------------------------------------------------------
⏷ Show the Full List of 54 DTT(s)
This Disease Is Related to 10 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCC11 DTWN7FC moderate Genetic Variation [54]
ABCC10 DTPS120 Strong Genetic Variation [55]
ABCC5 DTYVM24 Strong Genetic Variation [56]
ABCC6 DT582KR Strong Biomarker [57]
ATP12A DT5NLZA Strong Altered Expression [28]
SLC27A5 DT0TQS3 Strong Biomarker [58]
SLC28A1 DT0EQPW Strong Genetic Variation [59]
SLC28A3 DT4YL5R Strong Genetic Variation [60]
SLC35A2 DT0567K Strong Genetic Variation [61]
SLC45A2 DTNCJAT Strong Genetic Variation [62]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DTP(s)
This Disease Is Related to 14 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
NAT2 DER7TA0 Limited Biomarker [63]
CYP39A1 DEEG96X moderate Genetic Variation [64]
UGT1A3 DEF2WXN moderate Genetic Variation [65]
UGT1A5 DEPF954 moderate Genetic Variation [65]
UGT1A6 DESD26P moderate Genetic Variation [15]
UGT1A9 DE85D2P moderate Genetic Variation [65]
DCTD DEXL3P2 Strong Genetic Variation [24]
FMO3 DEP76YL Strong Genetic Variation [66]
G6PC3 DEE1B8O Strong Biomarker [67]
UGT1A10 DEL5N6Y Strong Genetic Variation [68]
UGT1A4 DELOY3P Strong Genetic Variation [68]
UGT1A7 DEZO4N3 Strong Genetic Variation [68]
UGT1A8 DE2GB8N Strong Genetic Variation [68]
UGT2B7 DEB3CV1 Strong Genetic Variation [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DME(s)
This Disease Is Related to 66 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADA2 OTGCV24S Limited Genetic Variation [69]
ASPG OT5E2EKR Limited Biomarker [70]
BRCA1 OT5BN6VH Limited Genetic Variation [71]
IL3 OT0CQ35N Limited Biomarker [72]
MCPH1 OTYT3TT5 Limited Genetic Variation [73]
ACAD8 OT3JI5GB moderate Biomarker [74]
BOC OTXBCY9W moderate Biomarker [75]
CD177 OTS79FNF moderate Biomarker [76]
CDAN1 OTCVZRG6 moderate Biomarker [77]
CHD2 OTRKL6YC moderate Biomarker [21]
CHPT1 OT4FJ0K3 moderate Genetic Variation [78]
DHDDS OTVLYBUS moderate Genetic Variation [78]
HUWE1 OTFH6BJS moderate Genetic Variation [21]
MTX1 OTLSDNZO moderate Genetic Variation [79]
SBDS OTHDCCIB moderate Genetic Variation [80]
TIMM50 OTWJNUQL moderate Genetic Variation [81]
AP3B1 OTYTIH5Q Strong Biomarker [51]
ASF1A OT4S44GP Strong Biomarker [82]
BTBD8 OT3A3RD7 Strong Genetic Variation [83]
CBFB OTIAC6W4 Strong Genetic Variation [84]
CREBZF OTO3TOEU Strong Biomarker [85]
CYCS OTBFALJD Strong Biomarker [86]
DIRAS1 OT07F6PE Strong Genetic Variation [87]
EIF6 OTEXMUED Strong Biomarker [88]
ERCC1 OTNPYQHI Strong Genetic Variation [89]
ERCC3 OTVAW3P1 Strong Posttranslational Modification [90]
ERCC4 OTFIOPG1 Strong Genetic Variation [91]
FCRL3 OTIFXFWL Strong Genetic Variation [92]
FHL3 OTMPRLZ5 Strong Biomarker [93]
GATA2 OTBP2QQ2 Strong Altered Expression [94]
GGTLC1 OTWJKUHQ Strong Biomarker [95]
GINS1 OTVQZMMQ Strong Biomarker [96]
GPSM3 OT2MO458 Strong Biomarker [97]
IFIT3 OTPGHZB9 Strong Altered Expression [98]
JAGN1 OTHBA8GT Strong Genetic Variation [99]
JPT1 OT6CRZEU Strong Genetic Variation [100]
LILRA3 OTBNQCOS Strong Biomarker [101]
LPIN2 OTRRTMXX Strong Genetic Variation [102]
MMS19 OTAXB34N Strong Biomarker [103]
MPP3 OTNOL0HA Strong Biomarker [104]
MYH11 OTVNVWY3 Strong Genetic Variation [84]
N4BP2L2 OTV2F04G Strong Biomarker [105]
NCOA5 OTOGWTWB Strong Biomarker [82]
NOTCH2NLA OTD5QPCI Strong Biomarker [106]
NT5C1A OTS7UF36 Strong Biomarker [107]
NUDT15 OTX8SZOT Strong Genetic Variation [108]
OR2AG1 OTEITRP4 Strong Biomarker [109]
PAK3 OT80M3BV Strong Biomarker [57]
PARP9 OT7K4494 Strong Biomarker [58]
PIK3C2A OTFBU4GD Strong Altered Expression [110]
PPP6R2 OTERHESI Strong Biomarker [111]
PSMD3 OT585WY8 Strong Genetic Variation [112]
PSTPIP1 OT4PGEAB Strong Genetic Variation [113]
RECQL OTPCH3JH Strong Genetic Variation [114]
REV1 OTHIKICX Strong Genetic Variation [115]
RNPC3 OTW5MKC1 Strong Biomarker [116]
RPS15 OT0WYZYG Strong Genetic Variation [87]
SEPTIN3 OTOZ6PIM Strong Genetic Variation [117]
SERPINB1 OT5RDUFO Strong Biomarker [118]
SRP54 OT9SGF3X Strong Genetic Variation [119]
SSB OTCCTPBR Strong Biomarker [101]
STAT2 OTO9G2RZ Strong Genetic Variation [120]
STAT5B OTZVPEBT Strong Biomarker [121]
SUCLA2 OTMZD4PW Strong Genetic Variation [122]
TGS1 OTM79LML Strong Genetic Variation [123]
TMTC3 OTMTTDYG Strong Biomarker [85]
------------------------------------------------------------------------------------
⏷ Show the Full List of 66 DOT(s)

References

1 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2 Autosomal recessive agammaglobulinemia: the third case of Ig deficiency due to a novel non-sense mutation.J Clin Immunol. 2014 May;34(4):425-7. doi: 10.1007/s10875-014-0033-4. Epub 2014 Apr 11.
3 Abatacept and granulocyte-colony stimulating factor in a patient with rheumatoid arthritis and neutropenia.Immunotherapy. 2017 Oct;9(13):1055-1059. doi: 10.2217/imt-2017-0065. Epub 2017 Oct 2.
4 Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice.JCI Insight. 2019 Dec 19;4(24):e132140. doi: 10.1172/jci.insight.132140.
5 Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One. 2015 Aug 5;10(8):e0134102.
6 A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep;391(9):953-963. doi: 10.1007/s00210-018-1517-1. Epub 2018 Jun 5.
7 Differential Behavior of Non-albicans Candida Species in the Central Nervous System of Immunocompetent and Immunosuppressed Mice.Front Microbiol. 2019 Jan 8;9:2968. doi: 10.3389/fmicb.2018.02968. eCollection 2018.
8 Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.
9 Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15;116(22):5325-35.
10 Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2018 Jul;19(7):987-998. doi: 10.1016/S1470-2045(18)30241-9. Epub 2018 Jun 4.
11 Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Pharmacogenomics. 2016 Jun;17(9):1089-112. doi: 10.2217/pgs-2015-0006. Epub 2016 Jun 7.
12 The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia.Br J Haematol. 2019 Feb;184(4):497-507. doi: 10.1111/bjh.15730. Epub 2018 Dec 27.
13 Clinical, genetic and immunological characteristics of 40 Chinese patients with CD40 ligand deficiency.Scand J Immunol. 2019 Oct;90(4):e12798. doi: 10.1111/sji.12798. Epub 2019 Jul 21.
14 Impairment of G-CSF receptor on granulocytic progenitor cells causes neutropenia in protein malnutrition.Nutrition. 2020 Jan;69:110540. doi: 10.1016/j.nut.2019.06.021. Epub 2019 Jun 27.
15 Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17.
16 Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.J Clin Pharmacol. 2016 Mar;56(3):349-54. doi: 10.1002/jcph.587. Epub 2015 Oct 26.
17 Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.Cancer Chemother Pharmacol. 2019 Apr;83(4):755-762. doi: 10.1007/s00280-019-03776-8. Epub 2019 Jan 25.
18 Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency.Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1241-1250. doi: 10.1073/pnas.1816143116. Epub 2019 Jan 9.
19 Biweekly cisplatin and gemcitabine with two different doses in non small cell lung cancer patients: A retrospective singlecenter experience.J BUON. 2018 Jul-Aug;23(4):1070-1076.
20 PEGylated IL-11 (BBT-059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome.Health Phys. 2018 Jul;115(1):65-76. doi: 10.1097/HP.0000000000000841.
21 Application of whole-exome sequencing to unravel the molecular basis of undiagnosed syndromic congenital neutropenia with intellectual disability.Am J Med Genet A. 2017 Jan;173(1):62-71. doi: 10.1002/ajmg.a.37969. Epub 2016 Sep 12.
22 Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice.J Anesth. 2017 Jun;31(3):397-404. doi: 10.1007/s00540-017-2311-9. Epub 2017 Jan 31.
23 STAT3 mutation impacts biological and clinical features of T-LGL leukemia.Oncotarget. 2017 Jun 27;8(37):61876-61889. doi: 10.18632/oncotarget.18711. eCollection 2017 Sep 22.
24 Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.Int J Hematol. 2015 Jun;101(6):543-53. doi: 10.1007/s12185-015-1766-4. Epub 2015 Mar 4.
25 Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.Pharmacogenomics. 2009 Jul;10(7):1139-46. doi: 10.2217/pgs.09.35.
26 Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.Pharmacogenomics J. 2018 Apr;18(2):275-280. doi: 10.1038/tpj.2017.12. Epub 2017 Apr 18.
27 Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.Inflamm Bowel Dis. 2015 Dec;21(12):2897-908. doi: 10.1097/MIB.0000000000000570.
28 Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.Chemotherapy. 2017;62(4):215-224. doi: 10.1159/000464273. Epub 2017 Apr 19.
29 Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.Clin Cancer Res. 2006 Dec 1;12(23):7033-8. doi: 10.1158/1078-0432.CCR-06-1246.
30 OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.Br J Cancer. 2015 Mar 3;112(5):857-65. doi: 10.1038/bjc.2015.5. Epub 2015 Jan 22.
31 Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.Br J Cancer. 2019 Aug;121(4):318-324. doi: 10.1038/s41416-019-0517-3. Epub 2019 Jul 15.
32 Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3723-3729.
33 Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Br J Clin Pharmacol. 2016 Feb;81(2):327-40. doi: 10.1111/bcp.12800. Epub 2015 Dec 25.
34 Antituberculosis Drug-Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors.Clin Pharmacol Ther. 2018 Aug;104(2):326-334. doi: 10.1002/cpt.924. Epub 2017 Nov 23.
35 An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients.Pharmacogenomics J. 2020 Jun;20(3):505-515. doi: 10.1038/s41397-019-0126-9. Epub 2019 Dec 9.
36 Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.Oncotarget. 2016 May 3;7(18):25291-303. doi: 10.18632/oncotarget.8052.
37 Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.Asian Pac J Cancer Prev. 2012;13(7):3461-4. doi: 10.7314/apjcp.2012.13.7.3461.
38 G protein-coupled receptor kinase-3-deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses.J Leukoc Biol. 2013 Dec;94(6):1243-51. doi: 10.1189/jlb.0213097. Epub 2013 Aug 9.
39 Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Eur J Clin Pharmacol. 2012 Apr;68(4):389-95. doi: 10.1007/s00228-011-1134-0. Epub 2011 Oct 20.
40 Coexistence of Gaucher Disease and severe congenital neutropenia.Blood Cells Mol Dis. 2019 May;76:1-6. doi: 10.1016/j.bcmd.2018.07.001. Epub 2018 Aug 10.
41 Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs.Pediatr Transplant. 2017 Nov;21(7):10.1111/petr.13033. doi: 10.1111/petr.13033. Epub 2017 Sep 4.
42 Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.J Heart Lung Transplant. 2010 May;29(5):509-16. doi: 10.1016/j.healun.2009.11.602. Epub 2010 Jan 12.
43 DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.Cancer Chemother Pharmacol. 2018 Jan;81(1):119-129. doi: 10.1007/s00280-017-3478-3. Epub 2017 Nov 13.
44 ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis.PLoS One. 2017 Sep 27;12(9):e0185254. doi: 10.1371/journal.pone.0185254. eCollection 2017.
45 A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba.
46 PKN1 kinase-negative knock-in mice develop splenomegaly and leukopenia at advanced age without obvious autoimmune-like phenotypes.Sci Rep. 2019 Sep 27;9(1):13977. doi: 10.1038/s41598-019-50419-2.
47 PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.Pharmacogenomics J. 2008 Apr;8(2):139-46. doi: 10.1038/sj.tpj.6500478. Epub 2007 Sep 18.
48 Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.J Clin Oncol. 2017 Apr 10;35(11):1231-1239. doi: 10.1200/JCO.2016.70.5350. Epub 2017 Feb 21.
49 Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis.Pharmacogenomics. 2016 Jul;17(10):1189-1205. doi: 10.2217/pgs-2015-0005. Epub 2016 Jul 6.
50 Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb;16(1):54-9.
51 Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood.Orphanet J Rare Dis. 2018 Mar 27;13(1):42. doi: 10.1186/s13023-018-0780-z.
52 Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res. 2006 Jul 1;12(13):3928-34. doi: 10.1158/1078-0432.CCR-05-2665.
53 Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.Hum Mutat. 2018 Apr;39(4):579-587. doi: 10.1002/humu.23399. Epub 2018 Jan 19.
54 The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.Pharmacogenomics J. 2017 Jul;17(4):319-324. doi: 10.1038/tpj.2016.23. Epub 2016 Mar 22.
55 Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.BMC Cancer. 2019 Mar 19;19(1):246. doi: 10.1186/s12885-019-5438-2.
56 ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015 Dec;25(12):573-83.
57 Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ?0 years.Am J Hematol. 2017 Oct;92(10):E567-E574. doi: 10.1002/ajh.24847. Epub 2017 Aug 17.
58 Comparing the profile of respiratory fungal pathogens amongst immunocompetent and immunocompromised hosts, their susceptibility pattern and correlation of various opportunistic respiratory fungal infections and their progression in relation to the CD4+T-cell counts.Indian J Med Microbiol. 2018 Jul-Sep;36(3):408-415. doi: 10.4103/ijmm.IJMM_18_258.
59 An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).Pharmacogenet Genomics. 2019 Aug;29(6):123-131. doi: 10.1097/FPC.0000000000000375.
60 Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.Clin Cancer Res. 2010 Jan 1;16(1):320-9. doi: 10.1158/1078-0432.CCR-09-1555. Epub 2009 Dec 22.
61 UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.Cancer Chemother Pharmacol. 2017 Jul;80(1):135-149. doi: 10.1007/s00280-017-3344-3. Epub 2017 Jun 5.
62 Homozygosity mapping and whole-exome sequencing to detect SLC45A2 and G6PC3 mutations in a single patient with oculocutaneous albinism and neutropenia.J Invest Dermatol. 2011 Oct;131(10):2017-25. doi: 10.1038/jid.2011.157. Epub 2011 Jun 16.
63 Sulphasalazine-induced leucopenia in a patient with renal dysfunction. J Clin Pharm Ther. 2003 Jun;28(3):239-42.
64 CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.BMC Cancer. 2015 Oct 16;15:725. doi: 10.1186/s12885-015-1776-x.
65 A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.Pharmacogenomics J. 2015 Dec;15(6):513-20. doi: 10.1038/tpj.2015.12. Epub 2015 Mar 17.
66 Novel Association between Flavin-Containing Monooxygenase 3 Gene Polymorphism and Antithyroid Drug-Induced Agranulocytosis in the Han Population.Ann Nutr Metab. 2019;74(3):200-206. doi: 10.1159/000497314. Epub 2019 Feb 27.
67 Inborn errors of metabolite repair.J Inherit Metab Dis. 2020 Jan;43(1):14-24. doi: 10.1002/jimd.12187. Epub 2019 Dec 29.
68 UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.Int J Clin Oncol. 2016 Aug;21(4):696-703. doi: 10.1007/s10147-015-0937-x. Epub 2015 Dec 28.
69 Novel Mutation in CECR1 Leads to Deficiency of ADA2 with Associated Neutropenia.J Clin Immunol. 2018 Apr;38(3):273-277. doi: 10.1007/s10875-018-0487-x. Epub 2018 Mar 21.
70 The sonographic appearance of cyclophosphamide-induced acute haemorrhagic cystitis.Clin Radiol. 1990 Apr;41(4):289-90. doi: 10.1016/s0009-9260(05)81670-8.
71 BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.Breast Cancer Res Treat. 2019 Apr;174(3):775-783. doi: 10.1007/s10549-018-05127-2. Epub 2019 Jan 11.
72 Characterisation of the porcine cytokines which activate the CD131(c) common sub-unit, for potential immune-augmentation.Cytokine. 2018 Feb;102:131-140. doi: 10.1016/j.cyto.2017.07.021. Epub 2017 Aug 12.
73 Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet Genomics. 2011 Sep;21(9):552-8. doi: 10.1097/FPC.0b013e328348e48f.
74 Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.Aliment Pharmacol Ther. 2019 Sep;50(5):484-506. doi: 10.1111/apt.15403. Epub 2019 Jul 25.
75 Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.Liver Int. 2014 May;34(5):707-19. doi: 10.1111/liv.12300. Epub 2013 Oct 9.
76 Prolonged neutropenia due to antihuman neutrophil antigen 2 (CD177) antibody after bone marrow transplantation.Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26388. Epub 2016 Dec 1.
77 A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.BMC Cancer. 2017 Mar 6;17(1):173. doi: 10.1186/s12885-017-3143-6.
78 Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.J Pharmacol Sci. 2019 May;140(1):20-25. doi: 10.1016/j.jphs.2019.03.004. Epub 2019 May 4.
79 Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.Rheumatology (Oxford). 2020 Apr 1;59(4):709-717. doi: 10.1093/rheumatology/kez343.
80 Shwachman-Bodian-Diamond syndrome (SBDS) protein deficiency impairs translation re-initiation from C/EBP and C/EBP mRNAs.Nucleic Acids Res. 2016 May 19;44(9):4134-46. doi: 10.1093/nar/gkw005. Epub 2016 Jan 13.
81 Mutations in TIMM50 cause severe mitochondrial dysfunction by targeting key aspects of mitochondrial physiology.Hum Mutat. 2019 Oct;40(10):1700-1712. doi: 10.1002/humu.23779. Epub 2019 May 17.
82 Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.BioDrugs. 2019 Aug;33(4):373-389. doi: 10.1007/s40259-019-00356-3.
83 Impact of high MIC of fluconazole on outcomes of Candida glabrata bloodstream infection: a retrospective multicenter cohort study.Diagn Microbiol Infect Dis. 2018 Oct;92(2):127-132. doi: 10.1016/j.diagmicrobio.2018.05.001. Epub 2018 Jun 19.
84 Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.Leukemia. 2007 Apr;21(4):725-31. doi: 10.1038/sj.leu.2404531. Epub 2007 Feb 8.
85 Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.Clin Cancer Res. 2012 Aug 1;18(15):4183-90. doi: 10.1158/1078-0432.CCR-12-1064. Epub 2012 Jun 6.
86 The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.Clin Rheumatol. 2020 Mar;39(3):813-821. doi: 10.1007/s10067-019-04784-y. Epub 2019 Nov 12.
87 A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.Ann Oncol. 2015 Sep;26(9):1923-1929. doi: 10.1093/annonc/mdv264. Epub 2015 Jun 19.
88 Shwachman-Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability.Br J Haematol. 2019 Mar;184(6):974-981. doi: 10.1111/bjh.15729. Epub 2018 Dec 26.
89 Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.Cancer Med. 2020 Jan;9(2):605-614. doi: 10.1002/cam4.2743. Epub 2019 Dec 3.
90 Microsomal epoxide hydrolase (EPHX1) polymorphisms are associated with aberrant promoter methylation of ERCC3 and hematotoxicity in benzene-exposed workers.Environ Mol Mutagen. 2013 Jul;54(6):397-405. doi: 10.1002/em.21786. Epub 2013 Jun 25.
91 Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Pharmacogenomics. 2014;15(12):1565-74. doi: 10.2217/pgs.14.107.
92 Disease phenotypes and gender association of FCRL3 single-nucleotide polymorphism -169T/C in Taiwanese patients with systemic lupus erythematosus and rheumatoid arthritis.J Rheumatol. 2011 Feb;38(2):264-70. doi: 10.3899/jrheum.100437. Epub 2010 Nov 15.
93 Evidence for defective Rab GTPase-dependent cargo traffic in immune disorders.Exp Cell Res. 2013 Sep 10;319(15):2360-7. doi: 10.1016/j.yexcr.2013.06.012. Epub 2013 Jun 26.
94 Diffuse parenchymal lung disease as first clinical manifestation of GATA-2 deficiency in childhood.BMC Pulm Med. 2015 Feb 10;15:8. doi: 10.1186/s12890-015-0006-2.
95 Asymptomatic hepatitis G virus infection in blood donors.Transfusion. 1997 Nov-Dec;37(11-12):1200-4. doi: 10.1046/j.1537-2995.1997.37111298088052.x.
96 Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest. 2017 May 1;127(5):1991-2006. doi: 10.1172/JCI90727. Epub 2017 Apr 17.
97 Regulation of Chemokine Signal Integration by Activator of G-Protein Signaling 4 (AGS4).J Pharmacol Exp Ther. 2017 Mar;360(3):424-433. doi: 10.1124/jpet.116.238436. Epub 2017 Jan 6.
98 Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells.Arthritis Res Ther. 2008;10(4):R91. doi: 10.1186/ar2475. Epub 2008 Aug 15.
99 Next-Generation Sequencing Reveals A JAGN1 Mutation in a Syndromic Child With Intermittent Neutropenia.J Pediatr Hematol Oncol. 2019 May;41(4):e266-e269. doi: 10.1097/MPH.0000000000001256.
100 Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Breast Cancer Res Treat. 2015 Jan;149(1):151-61. doi: 10.1007/s10549-014-3248-4. Epub 2014 Dec 24.
101 Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjgren's syndrome.Ann Rheum Dis. 2015 Nov;74(11):2070-5. doi: 10.1136/annrheumdis-2013-204441. Epub 2014 Jun 6.
102 Compound heterozygous LPIN2 pathogenic variants in a patient with Majeed syndrome with recurrent fever and severe neutropenia: case report.BMC Med Genet. 2019 Nov 14;20(1):182. doi: 10.1186/s12881-019-0919-3.
103 Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.PLoS One. 2012;7(10):e48350. doi: 10.1371/journal.pone.0048350. Epub 2012 Oct 31.
104 TLR5 signaling in murine bone marrow induces hematopoietic progenitor cell proliferation and aids survival from radiation.Blood Adv. 2017 Sep 14;1(21):1796-1806. doi: 10.1182/bloodadvances.2017006981. eCollection 2017 Sep 26.
105 Contributions to neutropenia from PFAAP5 (N4BP2L2), a novel protein mediating transcriptional repressor cooperation between Gfi1 and neutrophil elastase.Mol Cell Biol. 2009 Aug;29(16):4394-405. doi: 10.1128/MCB.00596-09. Epub 2009 Jun 8.
106 A novel notch protein, N2N, targeted by neutrophil elastase and implicated in hereditary neutropenia. Mol Cell Biol. 2004 Jan;24(1):58-70. doi: 10.1128/MCB.24.1.58-70.2004.
107 Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.Transplantation. 2019 Oct;103(10):2031-2056. doi: 10.1097/TP.0000000000002769.
108 Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15(R138C) knock-in mice.Leukemia. 2020 Mar;34(3):882-894. doi: 10.1038/s41375-019-0583-9. Epub 2019 Oct 24.
109 Impact of Chemotherapy Regimens on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Rectal Cancer Patients Receiving Intensity Modulated Radiation Therapy With Concurrent Chemotherapy From a Prospective Phase III Clinical Trial.Front Oncol. 2019 Apr 9;9:244. doi: 10.3389/fonc.2019.00244. eCollection 2019.
110 Atypical neuroleptic malignant syndrome - A case report.Asian J Psychiatr. 2019 Jun;43:7-8. doi: 10.1016/j.ajp.2019.04.007. Epub 2019 Apr 30.
111 Candidemia in a major regional tertiary referral hospital - epidemiology, practice patterns and outcomes.Antimicrob Resist Infect Control. 2017 Mar 11;6:27. doi: 10.1186/s13756-017-0184-1. eCollection 2017.
112 Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C.Hum Genet. 2015 Mar;134(3):279-89. doi: 10.1007/s00439-014-1520-7. Epub 2014 Dec 17.
113 PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome: A rare cause of childhood neutropenia associated with systemic inflammation and hyperzincemia.Pediatr Blood Cancer. 2019 Jan;66(1):e27439. doi: 10.1002/pbc.27439. Epub 2018 Sep 10.
114 Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.Cancer. 2012 May 1;118(9):2466-75. doi: 10.1002/cncr.26562. Epub 2011 Sep 28.
115 Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.Pharmacogenomics. 2014 May;15(7):941-50. doi: 10.2217/pgs.14.14.
116 The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients.Asian Pac J Allergy Immunol. 2021 Dec;39(4). doi: 10.12932/AP-211218-0465.
117 Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
118 Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia.J Mol Med (Berl). 2019 May;97(5):633-645. doi: 10.1007/s00109-019-01754-4. Epub 2019 Mar 7.
119 Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features. J Clin Invest. 2017 Nov 1;127(11):4090-4103. doi: 10.1172/JCI92876. Epub 2017 Oct 3.
120 Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.J Viral Hepat. 2009 Jun;16(6):388-96. doi: 10.1111/j.1365-2893.2009.01095.x. Epub 2009 Feb 5.
121 Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors.J Biol Chem. 2005 Apr 8;280(14):13364-73. doi: 10.1074/jbc.M407326200. Epub 2005 Jan 26.
122 Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.Scand J Gastroenterol. 2016;51(6):684-91. doi: 10.3109/00365521.2015.1133698. Epub 2016 Jan 14.
123 Clinical significance of lnc-AC145676.2.1-6 and lnc-TGS1-1 and their variants in western Chinese tuberculosis patients.Int J Infect Dis. 2019 Jul;84:8-14. doi: 10.1016/j.ijid.2019.04.018. Epub 2019 Apr 24.